Overview
- 70 inspections across 70 sites are on record.
- 105 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2023-05-05.
At a glance
Inspections
70
Sites
70
Observations
105
Career since
Apr 2015
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Bristol-Myers Squibb Company | 5 May 2023 | Biologics | On file |
| Kite Pharma, Inc. | 4 Mar 2022 | Biologics | |
| Pfizer Manufacturing Belgium NV | 2 Jul 2021 | Biologics | |
| Evaric Pharmaceuticals Inc. | 19 Mar 2020 | Human Drugs | |
| Bora Pharmaceutical Laboratories Inc. Zhongli Plant | 7 Feb 2020 | Human Drugs | On file |
Sites inspected
Bristol-Myers Squibb CompanyDevens, United States1 insp.
Kite Pharma, Inc.Frederick, United States1 insp.
Pfizer Manufacturing Belgium NVPuurs-Sint-Amands, Belgium1 insp.
Evaric Pharmaceuticals Inc.Hauppauge, United States1 insp.
Bora Pharmaceutical Laboratories Inc. Zhongli PlantTao Yuan Shi, Taiwan1 insp.
Co-investigators
Investigators who share inspections with this person.
Linda F Murphy5 shared
Deyaa Shaheen4 shared
Pratik S Upadhyay3 shared
Joshua P Wireman3 shared
Meisha R Waters3 shared
Meisha R Sampson3 shared
Graeme E Price2 shared
Jai P Singh2 shared
Jeffrey N Gerdes2 shared
Toyin B Oladimeji2 shared
Full investigator report
Get the verbatim findings behind Zhongren Wu's 105 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site